BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 33250293)

  • 21. ABCG2/BCRP: variants, transporter interaction profile of substrates and inhibitors.
    Safar Z; Kis E; Erdo F; Zolnerciks JK; Krajcsi P
    Expert Opin Drug Metab Toxicol; 2019 Apr; 15(4):313-328. PubMed ID: 30856014
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cellular Processing of the ABCG2 Transporter-Potential Effects on Gout and Drug Metabolism.
    Mózner O; Bartos Z; Zámbó B; Homolya L; Hegedűs T; Sarkadi B
    Cells; 2019 Oct; 8(10):. PubMed ID: 31597297
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification of ABCG2 as an Exporter of Uremic Toxin Indoxyl Sulfate in Mice and as a Crucial Factor Influencing CKD Progression.
    Takada T; Yamamoto T; Matsuo H; Tan JK; Ooyama K; Sakiyama M; Miyata H; Yamanashi Y; Toyoda Y; Higashino T; Nakayama A; Nakashima A; Shinomiya N; Ichida K; Ooyama H; Fujimori S; Suzuki H
    Sci Rep; 2018 Jul; 8(1):11147. PubMed ID: 30042379
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dacomitinib potentiates the efficacy of conventional chemotherapeutic agents via inhibiting the drug efflux function of ABCG2 in vitro and in vivo.
    Guo X; To KKW; Chen Z; Wang X; Zhang J; Luo M; Wang F; Yan S; Fu L
    J Exp Clin Cancer Res; 2018 Feb; 37(1):31. PubMed ID: 29458405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Measurement of Hepatic ABCB1 and ABCG2 Transport Activity with [
    Hernández Lozano I; Bauer M; Wulkersdorfer B; Traxl A; Philippe C; Weber M; Häusler S; Stieger B; Jäger W; Mairinger S; Wanek T; Hacker M; Zeitlinger M; Langer O
    Mol Pharm; 2020 Jan; 17(1):316-326. PubMed ID: 31790256
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comprehensive analysis of the tryptophan metabolome in urine of patients with acute intermittent porphyria.
    Gomez-Gomez A; Marcos J; Aguilera P; To-Figueras J; Pozo OJ
    J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():347-354. PubMed ID: 28666226
    [TBL] [Abstract][Full Text] [Related]  

  • 27. P-glycoprotein and breast cancer resistance protein restrict brigatinib brain accumulation and toxicity, and, alongside CYP3A, limit its oral availability.
    Li W; Sparidans RW; Wang Y; Lebre MC; Beijnen JH; Schinkel AH
    Pharmacol Res; 2018 Nov; 137():47-55. PubMed ID: 30253203
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lapatinib (Tykerb, GW572016) reverses multidrug resistance in cancer cells by inhibiting the activity of ATP-binding cassette subfamily B member 1 and G member 2.
    Dai CL; Tiwari AK; Wu CP; Su XD; Wang SR; Liu DG; Ashby CR; Huang Y; Robey RW; Liang YJ; Chen LM; Shi CJ; Ambudkar SV; Chen ZS; Fu LW
    Cancer Res; 2008 Oct; 68(19):7905-14. PubMed ID: 18829547
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Correlation between adenosine triphosphate (ATP)-binding cassette transporter G2 (ABCG2) and drug resistance of esophageal cancer and reversal of drug resistance by artesunate.
    Wang L; Liu L; Chen Y; Du Y; Wang J; Liu J
    Pathol Res Pract; 2018 Sep; 214(9):1467-1473. PubMed ID: 30104076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of the Abcg2 transporter in plasma, milk, and tissue levels of the anthelmintic monepantel in mice.
    Gunes Y; Blanco-Paniagua E; Anlas C; Sari AB; Bakirel T; Ustuner O; Merino G
    Chem Biol Interact; 2024 Jun; 398():111117. PubMed ID: 38906501
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Assessment of ABCG2-mediated transport of xenobiotics across the blood-milk barrier of dairy animals using a new MDCKII in vitro model.
    Wassermann L; Halwachs S; Baumann D; Schaefer I; Seibel P; Honscha W
    Arch Toxicol; 2013 Sep; 87(9):1671-82. PubMed ID: 23652544
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Determination of functional ABCG2 activity and assessment of drug-ABCG2 interactions in dairy animals using a novel MDCKII in vitro model.
    Wassermann L; Halwachs S; Lindner S; Honscha KU; Honscha W
    J Pharm Sci; 2013 Feb; 102(2):772-84. PubMed ID: 23192864
    [TBL] [Abstract][Full Text] [Related]  

  • 33. ABC-transporter gene-polymorphisms are potential pharmacogenetic markers for mitoxantrone response in multiple sclerosis.
    Cotte S; von Ahsen N; Kruse N; Huber B; Winkelmann A; Zettl UK; Starck M; König N; Tellez N; Dörr J; Paul F; Zipp F; Lühder F; Koepsell H; Pannek H; Montalban X; Gold R; Chan A
    Brain; 2009 Sep; 132(Pt 9):2517-30. PubMed ID: 19605531
    [TBL] [Abstract][Full Text] [Related]  

  • 34. P-glycoprotein (MDR1/ABCB1) and Breast Cancer Resistance Protein (BCRP/ABCG2) limit brain accumulation of the FLT3 inhibitor quizartinib in mice.
    Wang J; Gan C; Retmana IA; Sparidans RW; Li W; Lebre MC; Beijnen JH; Schinkel AH
    Int J Pharm; 2019 Feb; 556():172-180. PubMed ID: 30553002
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hyperuricemia influences tryptophan metabolism via inhibition of multidrug resistance protein 4 (MRP4) and breast cancer resistance protein (BCRP).
    Dankers AC; Mutsaers HA; Dijkman HB; van den Heuvel LP; Hoenderop JG; Sweep FC; Russel FG; Masereeuw R
    Biochim Biophys Acta; 2013 Oct; 1832(10):1715-22. PubMed ID: 23665398
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Transmembrane Domain Single-Nucleotide Polymorphisms Impair Expression and Transport Activity of ABC Transporter ABCG2.
    Sjöstedt N; van den Heuvel JJMW; Koenderink JB; Kidron H
    Pharm Res; 2017 Aug; 34(8):1626-1636. PubMed ID: 28281205
    [TBL] [Abstract][Full Text] [Related]  

  • 37. P-Glycoprotein (MDR1/ABCB1) Restricts Brain Penetration of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib, While Cytochrome P450-3A (CYP3A) Limits Its Oral Bioavailability.
    van Hoppe S; Rood JJM; Buil L; Wagenaar E; Sparidans RW; Beijnen JH; Schinkel AH
    Mol Pharm; 2018 Nov; 15(11):5124-5134. PubMed ID: 30247919
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Erlotinib (Tarceva, OSI-774) antagonizes ATP-binding cassette subfamily B member 1 and ATP-binding cassette subfamily G member 2-mediated drug resistance.
    Shi Z; Peng XX; Kim IW; Shukla S; Si QS; Robey RW; Bates SE; Shen T; Ashby CR; Fu LW; Ambudkar SV; Chen ZS
    Cancer Res; 2007 Nov; 67(22):11012-20. PubMed ID: 18006847
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Reversal effect of FW-04-806, a macrolide dilactone compound, on multidrug resistance mediated by ABCB1 and ABCG2 in vitro and in vivo.
    Zhang Z; Ma C; Li P; Wu M; Ye S; Fu L; Xu J
    Cell Commun Signal; 2019 Sep; 17(1):110. PubMed ID: 31472682
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacological Evaluation of Dotinurad, a Selective Urate Reabsorption Inhibitor.
    Taniguchi T; Ashizawa N; Matsumoto K; Saito R; Motoki K; Sakai M; Chikamatsu N; Hagihara C; Hashiba M; Iwanaga T
    J Pharmacol Exp Ther; 2019 Oct; 371(1):162-170. PubMed ID: 31371478
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.